|
gptkbp:instanceOf
|
antineoplastic agent
topoisomerase inhibitor
|
|
gptkbp:approvalYear
|
1983
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:L01CB01
|
|
gptkbp:CASNumber
|
gptkb:33419-42-0
|
|
gptkbp:color
|
white to off-white powder
|
|
gptkbp:contraindication
|
severe hepatic impairment
severe bone marrow suppression
|
|
gptkbp:discoveredBy
|
gptkb:Sandoz
|
|
gptkbp:drugClass
|
podophyllotoxin derivative
|
|
gptkbp:eliminationHalfLife
|
4-11 hours
|
|
gptkbp:excretion
|
urine
bile
|
|
gptkbp:hasMolecularFormula
|
C29H32O13
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Etoposide
|
|
gptkbp:IUPACName
|
gptkb:4'-Demethylepipodophyllotoxin_9-[4,6-O-(R)-ethylidene-β-D-glucopyranoside]
|
|
gptkbp:KEGGID
|
gptkb:D00125
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits DNA topoisomerase II
|
|
gptkbp:MeSH_ID
|
gptkb:D004891
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
588.56 g/mol
|
|
gptkbp:origin
|
derived from podophyllotoxin
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL445
gptkb:DB00773
33513
36462
|
|
gptkbp:riskFactor
|
gptkb:secondary_leukemia
hypersensitivity reactions
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
immunosuppression
hair loss
low blood cell counts
mouth sores
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:storage
|
store at 20-25°C
|
|
gptkbp:synonym
|
gptkb:VP-16
|
|
gptkbp:UNII
|
6PLQ3CP4P3
|
|
gptkbp:usedFor
|
gptkb:cancer
leukemia
testicular cancer
Small Cell Lung Cancer
gastric cancer
|
|
gptkbp:bfsParent
|
gptkb:Small_Cell_Lung_Cancer
|
|
gptkbp:bfsLayer
|
5
|